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Abstract 
Placebo’s (positive expectancies producing positive outcomes) and nocebo’s (negative 
expectancies producing negative outcomes) are real and measurable effects. Real as 
these effects may be, predicting individuals that may be susceptible to placebo/nocebo 
effects has been inconsistent. The present study examined whether measures designed 
to assess somatization (MSPQ), catastrophizing (PCS) and childhood trauma (CTQ) 
would predict placebo and nocebo membership. In addition, measures designed to 
assess anxiety (ASI) anxiety about pain (PASS) and depression (BDI) were evaluated 
to determine whether anxiety or depression mediates responsiveness. The Hargreaves 
Thermal Withdrawal test and the submaximal effort tourniquet technique were employed 
as pain vehicles for the measurement of group differences. No significant effects of 
planned analyses were observed. However, unplanned analyses of childhood trauma 
subscales indicated that physical and emotional abuse predicted placebo response. 
Additionally, emotional neglect trended toward predicting nocebo responsiveness. 
These results indicate that further studies, correcting for weaknesses, is warranted. 
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 1 
Introduction 
Placebo (I will please) and nocebo (I will harm) are real phenomenon that have 
been extensively studied but are not well understood (Benedetti et al. 2007). The term 
placebo is practically ubiquitous in contemporary language and has a lengthy history. 
The use of the word placebo dates back several centuries in medical literature with the 
first reported controlled placebo study conducted in 1799 (Price, Finniss, & Benedetti, 
2008). Geers, Helfer, Kosbab, Weiland and Landry (2005) pointed out that “placebos 
have been described as one of the most powerful agents of symptom relief in medicine” 
and argue that prior to the beginning of the 20th century most treatments for illness and 
disease were placebo.  
Nocebo, on the other hand, is a newer term that is rarely used in lay language or 
academia. According to Benedetti and Amanzio (1996) the term nocebo was introduced 
by Kissel and Barrucand in 1974 to distinguish “the pleasing and salubrious effects of 
placebo from the noxious effects.” This distinction, though important, does little to 
eliminate confusion between the two terms. For example, if one does a PubMed search 
for nocebo, large numbers of papers will be found with placebo in the title and nocebo in 
the text. It seems clear that the field generally considers nocebo to fall under the 
umbrella of placebo, an assumption that may be dispelled by considering precise 
definitions of the two terms. As noted by Grünbaum (1981), a fundamental problem to 
advancing the field of placebo research has been one of definition.  
Important Distinctions 
The author will begin by clarifying the difference between placebo and the 
placebo effect. While it may seem intuitive that there is a difference, the distinction is 
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often muddled or missing in related literature. For example, Olchansky (2007) states a 
“placebo is a sham, often a pill, but any intervention purported to be therapeutic. 
Without direct physiologic or pharmacologic activity, a placebo somehow provides 
benefit or apparent benefit. Nocebo is a sham, without direct physiologic or 
pharmacological activity, that causes harm or apparent harm.” Note the lack of 
distinction for placebo effect.  
On the other hand, Stewart-Williams and Podd (2004) posited the following 
definitions that included such a distinction. “A placebo is a substance or procedure that 
has no inherent power to produce an effect that is sought or expected.” Followed by a 
definition for placebo effect, “A placebo effect is a genuine psychological or 
physiological effect, in a human or another animal, which is attributable to receiving a 
substance or undergoing a procedure, but is not due to the inherent powers of that 
substance or procedure.”  
Benedetti, Carlino and Pollo (2010) echo the immediately preceding definition by 
stating “A real placebo effect is a psychobiological phenomenon occurring in the 
patient’s brain after the administration of an inert substance, or of a sham physical 
treatment such as sham surgery, along with verbal suggestions (or any other cue) of 
clinical benefit.” Colloca and Benedetti (2007) then state for nocebo and nocebo effect 
the following, “If positive verbal suggestions, which are typical of the placebo effect, are 
reversed in the opposite direction, a nocebo effect can be obtained. Therefore, the 
study of the nocebo effect is the study of the negative psychosocial context around the 
patient and the treatment, and its neurobiological investigation is the analysis of the 
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effects of this negative context on the patient’s brain and body.” In short, nocebo is the 
opposite of placebo either with pill or procedure and its observed effect or effects. 
Taken together, the Stewart-Williams and Podd definitions provide the most 
complete framework from which to work. Now one only needs to make a minor 
amendment to clarify the meaning of nocebo and nocebo effect:  
A placebo or nocebo is a substance or procedure that has no inherent 
power to produce an effect that is sought or expected. 
 
A placebo effect is a genuine positive psychological or physiological effect, 
in a human or another animal, which is attributable to receiving a 
substance or undergoing a procedure, but is not due to the inherent 
powers of that substance or procedure. A nocebo effect is a genuine 
negative psychological or physiological effect, in a human or another 
animal, which is attributable to receiving a substance or undergoing a 
procedure, but is not due to the inherent powers of that substance or 
procedure.  
 
The author argues that the amendment is necessary because it provides effect 
directionality and thus, more clearly, delineates placebo from nocebo. Now that working 
definitions for placebo and nocebo have been established, the remaining discussion will 
encompass a brief review of issues related to placebo/nocebo effects, pain and its 
relationship to the placebo response. 
What is known: A brief review. 
 Much of the knowledge of the placebo effect comes from pain studies with and 
without neuropharmacological approaches (Amanzio and Benedetti, 1999; Benedetti & 
Amanzio, 1997; Hoffman et al., 2005). The literature generally suggests that placebo 
and nocebo responses are a function of conditioning and/or expectation (Benedetti et 
al., 2003; 2007; Colloca and Benedetti, 2007; Colloca et al. 2008; Enck et al. 2008; 
Geers et al., 2006; Klosterhalfen and Enck, 2008; Klosterhalfen et al., 2009; Olshancky, 
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2007; Stewart-Williams, 2004; Stewart-Williams and Podd, 2004; Voudouris et al., 
1990),with reward, social learning and memory also implicated (Benedetti, Carlino & 
Pollo, 2010). 
Expectancy 
 Expectancy theory has gained ground in recent years, largely supplanting similar 
mental constructs such as faith and hope (Peck & Coleman, 1991). Expectancy as a 
construct embodies an intuitive understanding of what the placebo effect is, “A placebo 
produces an effect because the recipient expects it to. The placebo elicits an 
expectation for a particular effect, and the expectation produces that effect” (Stewart-
Williams and Podd, 2004). 
Benedetti, Carlino & Pollo (2010) highlight two studies that demonstrate how 
strongly expectation is linked to pain and placebo responsiveness. Both studies 
investigated the role of the prefrontal cortex and placebo responsiveness. In the first 
study, Benedetti et al. (2006) studied Alzheimer patients in initial stages and after one 
year to evaluate the effectiveness of a placebo component of therapy the patients were 
receiving. The placebo component of therapy was correlated with a cognitive status as 
assessed by the Frontal Assessment Battery (FAB) test and functional connectivity 
among different brain regions assessed by electroencephalographic connectivity 
analysis. It was found that patients with lower FAB scores had lower placebo treatment 
responsiveness. Additionally, it was observed that disruption of placebo responsiveness 
occurred at the same time that prefrontal lobe connectivity to the rest of the brain was 
reduced. 
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Next, Krummenacher et al. (2010) used repetitive transcranial magnetic 
stimulation (rTMS) to transiently disrupt right and left dorsolateral prefrontal cortex (r/l 
dlpfc) functioning in a heat pain paradigm. This study found that placebos significantly 
increased pain threshold/tolerance and that disruption of r/l dlpfc using rTMS completely 
blocked placebo analgesia. In other words, “no prefrontal control, no placebo response” 
(Benedetti et al., 2010). 
Conditioning 
            Classical conditioning comprises the second major theoretical approach to the 
placebo effect. In general, applying conditioning to the placebo effect requires the drug 
or active ingredient to be the unconditioned stimulus (US) and the unlearned response 
to the active ingredient to be the unconditioned response (UR). In the course of any 
number of paradigms, the US would be paired with a neutral stimulus such as pill 
casings, syringes or even to objects, places, people and the procedures themselves. 
Through repeated associations with the US the neutral stimuli become conditioned 
stimuli (CS) capable of producing an effect similar to that of the active ingredient, which 
would be considered a conditioned response (CR). Thus, in a conditioning framework 
the placebo would be considered the CS and the placebo effect the CR (Stewart-
Williams and Podd, 2004). 
Much of the support for the classical conditioning paradigm comes from research on 
nonhuman animals and has been demonstrated with a variety of drugs and systems. 
Hernstien (1962) demonstrated that rats conditioned with injections of amphetamines 
when injected with saline exhibited behavior similar to that seen by amphetamine 
injection. Ader and Cohen (1975) paired novel saccharine flavored liquid with 
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cyclophosphamide, an immunosuppressant. After several pairings, the saccharine 
solution (CS, placebo) would elicit immunosuppression (CR, placebo effect). This was 
groundbreaking work as it was not generally believed at the time that conditioning could 
affect the immune system (Stewart-Williams and Podd, 2004). 
As with many academic topics, scholars tend to prefer one theory over another, in this 
case pitting expectancy (Kirsch, 1991) against conditioning (Voudouris et al., 1989; 
1990). However, as with many dichotomies there is often the overlooked third choice of 
both. In 2003, Benedetti et al. demonstrated in experimental pain models and Parkinson 
models that “conditioning is actually mediated by expectations and that expectations do 
not affect conditioned responses.” While it may not be clear what relationship 
expectancy and conditioning might have with each other, the literature shows that 
expectancy or previous exposure (conditioning) or both are necessary for the placebo 
effect to take place. 
Mechanisms and diseases 
Pain, as previously mentioned, is the paradigm utilized most when studying 
placebo and nocebo effects. It provides an easy platform from which to manipulate 
variables. This flexibility has enabled researchers to articulate the neurological 
mechanisms involved with pain and placebo/nocebo responses. It has been 
demonstrated placebos activate endogenous opioids (analgesia) that decrease pain 
response and nocebos activate an opponent hyperalgesic nonopioid system 
(cholecystokinin, CCK) that increase pain responsiveness (Amanzio and Benedetti, 
1999; Benedetti, 2007; Benedetti & Amanzio, 1997; Benedetti et al., 2007; Colloca and 
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Benedetti, 2007; Colloca et al., 2008; Enck et al., 2008; Klosterhalfen and Enck, 2008; 
Kong et al., 2008). 
 Though pain has been one of the most intensively studied areas of placebo and 
nocebo, a number of other conditions have been studied using a placebo paradigm. As 
a result, researchers are better able to articulate the mechanisms involved. Next to pain, 
Parkinson’s disease has been well described and studied in placebo settings. It is 
generally thought to generate an expectation induced release of dopamine in the 
striatum and recorded changes of firing patterns of sub-thalamic nucleus neurons as a 
result have been observed (Benedetti et al., 2004). According to Benedetti’s (2008) 
review of placebo and placebo effects across diseases and treatments, depression has 
differential metabolic responses in different brain regions, thought to be related to 
inhibition of serotonin reuptake. Furthermore the review showed that addiction had 
demonstrated changes in metabolic activity in various brain regions and the 
cardiovascular system has demonstrated reductions of β-adrenergic activity, all in 
response to placebo. Additionally, it was also shown that conditioning of opioid 
receptors in respiratory centers has been seen as a result of pharmacological 
preconditioning and the immune system has been documented to respond to 
pharmacological preconditioning as well, especially to immunosuppressive drugs. 
Finally, it was reported that conditioning of some hormones has been observed for the 
endocrine system as a result of pharmacological preconditioning with 5-HT receptor 
agonists. 
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Arguments against the placebo effect 
Despite the wealth of evidence documenting real placebo and nocebo effects, it 
is important to note that the literature is not consistent. Three meta-analytic studies 
have shown that depending on design placebo effect sizes can range from small in 
placebo only treatment designs (Hrobjartssen & Gøetsche, 2001; 2004) to large effect 
sizes in analgesic pain studies (Hrobjartssen & Gøetsche, 2006). These studies suggest 
that many placebo effects can be attributed to poor study design, spontaneous 
remission and regression to the mean and is, therefore, not as ubiquitous as the 
literature might suggest or even non-existent. Though it is important to note that poor 
design, remission and statistical regressions could influence the effect size of placebo 
response, it is also important to note that these meta-analyses have been challenged on 
a number of methodological issues. The primary complaint was one of directly 
comparing conditions that are not readily comparable (Meissner et al., 2007; Stewart-
Williams and Podd, 2004). Regardless of the effect size that may or may not be 
observed in a particular set of studies it is clear that the literature as a whole considers 
the placebo and nocebo effects to be real effects and one of serious academic inquiry.  
Susceptibility to the placebo and nocebo effect 
Scholars like Liberman (1968) and Jospe (1978) have endeavored to find 
evidence of a placebo-prone personality. The results, however, have been generally 
weak and insignificant (Gelfand, Gelfand & Rardin, 1965; Shapiro and Shapiro, 1997; 
Turner et al., 1994) or inconsistently present across different trials (Kaptchuk et al, 
2008). Geers et al. (2005) suggested that basic methodological problems, poor 
instrument reliability and factors such as spontaneous remission or regression to the 
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mean rather than a placebo effect may be impacting whether or not placebo personality 
traits or situations can reliably emerge. These are the same problems mentioned in the 
studies by Hrobjartsson and Gøtzsche (2001, 2004, 2006) and recognized by others 
(Stewart-Williams, 2004; Stewart-Williams and Podd, 2004; Enck, Benedetti & 
Schedlowski, 2008; Benedetti, Carlino & Pollo, 2010).  
The literature is clear, however, that placebo responders do exist. Kosterhalfen 
and Enck (2008) report that the overall placebo response rate to be around 40%, with 
variations on response rates depending on the disorder examined. For example, 
response rates of 29% in depression and 21% in migraine prophylaxis were reported 
while response rates of 26.9% to 56% were found in pain studies (Price, Finniss & 
Benedetti, 2008) and 75% placebo response rates found in a metaanalytic study of anti-
depressive medication trials by Kirsch and Sapirstein (1998). 
Recently, two genetic studies have tried to identify placebo responders. One 
study examined genetic variants related to serotonin and its role in placebo responding 
and social anxiety. It was found that only subjects homozygous for the long allele of the 
5-HTTLPR (serotonin transporter-linked polymorphic region) or the G variant of the 
TPH2 (tryptophan hydroxylase-2) gene promoter G-703T exhibited reduced stress 
related activity in the amygdala during placebo response. Additionally, the TPH2 
polymorphism was found to be a significant predictor of clinical placebo response 
(Furmark et al. 2008). The next genetic study examined the relationship between 
placebo responsiveness and polymorphisms in genes encoding for the monoamines 
catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAO A) in 
participants with major depressive disorder. It was found that individuals with G or G/G 
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forms of MAO A had significantly lower magnitude of placebo response compared with 
other genotypes and that individuals with the ValMet COMT polymorphism showed a 
trend toward lower magnitude of placebo response (Leuchter et al. 2009). Exciting as 
finding placebo responders through genetic techniques may be additional studies are 
needed to confirm and elaborate these results. 
In General, research that utilizes placebo is assessing medical treatment 
effectiveness by comparing active treatment groups with placebo groups but not with a 
no-placebo control group (Geers et al., 2006; Ader, 2000). Less than 4% of placebo 
studies have included a no-placebo control group in which to evaluate the effect claimed 
(Ernst and Resch, 1995; Fisher, 2000; Geer et al., 2005). A major problem with omitting 
a no placebo group is that it calls into question the comparative accuracy of the effect 
sizes observed and reported in such groups. Given this problem, the certainty that no 
consistent placebo responder can be found is called into question. 
Pain as a Vehicle for Understanding Placebo and Nocebo 
Pain is mentioned throughout this paper as the most understood and articulated 
modality for placebo and nocebo effects. It is a useful paradigm for examining these 
effects as it is easily manipulated in experimental situations and avoids some ethical 
dilemmas that may be seen in other placebo/nocebo studies (e.g. giving suggestions of 
symptom worsening to major depressive individuals). It is necessary then to discuss 
briefly pain and factors that are known to influence it. 
 The International Association for the study of Pain (IASP) has defined pain as 
“an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” (Merskey and Bogduk, 1994). 
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Loeser and Melzack (1999) describe three broad categories of pain. 1) Transient pain, 
which is elicited by activation of nociceptive transducers in the skin and other tissues of 
the body but do not require tissue damage. This type of pain is ubiquitous in daily life 
and is rarely a cause in seeking health care. 2) Acute pain, which is activated by 
substantial injury of bodily tissue and the activation of nociceptive transducers at the 
local site of tissue damage. Individuals typically seek medical care for this type of injury. 
3) Chronic pain, which is pain that is commonly triggered by an injury or disease and is 
commonly perpetuated by factors other than the cause of the pain. Loeser and Melzack 
(1999) further suggest that all types of chronic pain lead people to seek health care, 
however treatment is often not effective. They state that chronic pain is unrelenting and 
attribute this to stress, environmental and affective factors that may be superimposed 
on the original damaged tissue, contributing to its intensity and persistence.  
The American academy of Pain Management (2003) claims that for the previous 
year approximately 57% of adult Americans reported experiencing recurring or chronic 
pain, 62% of which reported being in pain for more than one year with 40% noting they 
were in constant pain. Gatchel (2004a, 2004b) indicates the pervasive nature of pain is 
a medical problem by stating that it affected over 50 million Americans, incurs a cost of 
over $70 billion annually in health care and lost productivity and accounts for more than 
80% of all clinical visits. Indeed the U.S. congress, in recognition of the problem, 
declared 2001-2010 as the Decade of Pain Control and Research. Further, the Joint 
commission on Accreditation of Healthcare Organization has implemented a 
requirement that physicians consider pain to be the fifth vital sign, in addition to pulse, 
blood pressure, core temperature and respiration (Gatchel et al. 2007). 
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Nonphysiological Factors that Influence the Experience of pain 
Pain has an urgent primitive quality that is responsible for its emotional qualities 
that are unlike any other sensory experience and the intensity with which it is 
experienced can be affected by a number of subjective experiences that produce 
differing responses by individuals under comparable circumstances (Kandel, Schwartz 
and Jessel, 2000). Conceptually there are a number of nonphysiological factors that can 
influence the perception of pain, for this discussion the factors being considered are 
anxiety, catastrophizing, somatization, depression and childhood trauma. 
Anxiety 
Anxiety is generally considered to be worry about future events and can lead to 
misinterpretation of body states, a generalized state of worry, phobias or specific 
disorders related to specific traumatic events (DSM-IV-TR; American Psychiatric 
Association, 2000). It is known to have physiological effects such as increased arousal 
(Cuthbert et al., 2003), and has been demonstrated to have a significant impact on the 
perceived intensity of painful stimuli, specifically in the context of placebo and nocebo 
studies (Colloca & Benedetti, 2007; Benedetti et al., 2006). It has been demonstrated 
that reduction of anxiety in placebo studies will reduce pain perception and that 
increases in anxiety during nocebo studies will increase pain perception (Benedetti and 
Amanzio, 1997; Benedetti et al., 1997; Benedetti et al., 2006; Colloca and Benedetti, 
2007) 
Because of its strong association with pain and pain perception (Benedetti et al., 
2006; 2007; Colloca and Benedetti, 2007; Gatchel et al., 2007; Geers et al., 2005; 
Keogh et al., 2006; Loeser and Melzack, 1999; Ploghous et al., 2001) and the degree to 
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which it has been experimentally manipulated made anxiety an examined variable in 
this study. 
  
Catastrophizing 
Catastrophizing is considered a tendency to exaggerate, focus and emphasize 
negative aspects of painful situations (Turner & Aaron, 2001). It has been characterized 
as a coping mechanism and appraisal or belief system (Sullivan et al., 2001). 
Individuals with a tendency to catastrophize are thought to reflect a persistent life 
course trait (Sullivan, Bishop & Pivik, 1995).  
Sullivan et al. (2008) conducted a study to evaluate the relationship between 
catastrophizing and placebo responsiveness and found that high catastrophizers were 
more likely to respond to placebo suggestion than low catastrophizers and while 
receiving active treatment high catastrophizers responded significantly less than low 
catastrophizers. This suggests that catastrophizers may be more susceptible to nocebo 
suggestions than non-catastrophizers. Due to its consistent relationship to painful 
situations, well-articulated foundation and the important role it plays in the perceived 
intensity of painful experience and emotional distress (Sullivan et al., 2001), 
catastrophizing was a variable of interest in this study.  
Somatization 
It is important to understand that certain patients use their physical 
symptoms as a way of dealing with, and communicating about, their 
emotional lives (somatization). That is to say, in this type of symptom 
magnification, physical symptoms may be easier to accept as causing 
current unhappiness and discontent than admitting that some 
psychological reason is contributing to it (Gatchel, 2004). 
 
14 
 
Geers, Helfer, Wieland & Kosbab (2006) examined the role somatic focus might have in 
placebo responders. They hypothesized that somatic focus would influence the 
response rates of individuals in an unconditional situation as compared to individuals in 
a conditional situation or controls. Results indicated that individuals given an 
unambiguous (unconditional) situation and told to focus on physical symptoms (somatic 
focus) were indeed more likely to report more placebo symptoms than the other two 
groups.  
This study suggests that somatizer’s would be susceptible to both placebo and 
nocebo effects due to their attention to physical changes by definition. Because of 
somatization’s relationship to pain as a coping mechanism and the influence it may 
have on placebo/nocebo effects, it was considered a factor in this study. 
Depression 
Depression is another psychological factor whose relationship to pain cannot be 
ignored. A literature review by Bair, Robinson, Katon and Kroenke (2003) found that on 
average 65% of patients with depression experienced one or more pain symptoms and 
that depression was observed in anywhere from 5 to 85% of patients with pain 
conditions.  
As mentioned earlier, the meta-analysis conducted by Kirsch and Sapirstein 
(1998) indicating a 75% placebo response rate in anti-depressive medication trials 
dictates that depression needed consideration as a variable in this study. 
Childhood Trauma 
Of additional interest is the consideration the role childhood trauma may have on 
pain perception. Research has demonstrated that early childhood trauma and adversity 
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is predictive for the onset of back pain in adulthood (Kopec and Sayre, 2005) and has 
been related to poor outcome following back surgery (Shofferman et al., 1993). It is 
believed that childhood trauma involving abuse or neglect may influence the way one 
perceives future painful events (Fillingim and Edwards, 2005; Heckman and Westefeld, 
2006) based on past experiences and was therefore included as a consideration in this 
study. 
Purpose and hypotheses 
Given the information presented thus far, it is the author’s goal to evaluate whether the 
nonphysiological factors of anxiety, catastrophizing, somatization, depression and 
childhood trauma will influence an individual’s response to placebo and nocebo 
conditions. This study evaluated these factors using a placebo group, nocebo group and 
control group design, which allowed the clearest distinction between groups. 
Based on evaluation of material presented to this point the author hypothesized 
that subjects given an inert pill and a positive verbal suggestion (placebo) will report 
experiencing less pain than controls and that subjects given an inert pill and negative 
verbal suggestion (nocebo) will report experiencing more pain than controls in a study 
utilizing ischemic arm pain,. Additionally, based on the literature, it is the author’s 
assertion that somatization, catastrophizing and childhood trauma represent a stable 
coping style and unchanging personal experiences, respectively, where anxiety and 
depression represent transient variable states. Given this assertion, the author 
hypothesized that individuals in the top ten percent of somatizers (high somatizers) will 
report lower levels of pain in the placebo condition in comparison to the bottom fifty 
percent of somatizers (low somatizers) and controls with the top ten percent reporting 
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higher pain ratings in the nocebo condition than the bottom fifty percent and controls. In 
the case of childhood trauma, the author suggests that these negative experiences will 
present a negative outlook (expectation) in painful situations. Thus, it was hypothesized 
that individuals in the top 10 percent of trauma victims (high trauma) will report higher 
pain ratings in the nocebo condition as compared to those in the bottom 50 percent (low 
trauma) and those in placebo and control conditions. In addition, it is hypothesized that 
anxiety and depression will mediate responses to the Nocebo and Placebo groups. 
Methods 
Participants 
90 healthy participants, 62 females and 28 males, were recruited from 
psychology classes at the University of New Orleans and randomly assigned to one of 
three groups (nocebo, placebo and control) after screening for chronic or current pain, 
to include back pain, neuropathic pain and headaches; mental distress; cardiovascular 
disorders; asthma; arthritis; as well as those who indicate they have taken aspirin or any 
other analgesic (prescription or over the counter), cough medicine, sedatives, 
tranquilizers, antidepressants or alcohol consumption on the day of testing. Following 
the screening process all subjects signed a written informed consent form in which the 
experimental procedure was described in detail. 
An evaluation of a large data set from a questionnaire distributed at the 
University of New Orleans (2008) that contained two of the questionnaires to be 
included in this study (the MSPQ and PCS), was conducted to determine the minimum 
number of participants that would be required to conduct this study. Results indicated 
that 135 participants (45 per group) is the minimum number necessary for reasonable 
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assurance that random assignment to each group will include enough members for 
each variable to allow comparisons. The proposed number of 135 participants was 
approved by committee, however, due to unanticipated time constraints the number or 
participants at the time of writing is 90. 
Measures 
Modified Somatic Perception Questionnaire.  
The MSPQ is administered to measure somatic arousal. It is a 13 item 4-point 
Likert scale ranging from 1 (not at all) to 4 (very much) that demonstrates adequate 
validity and reliability (Main, 1983). 
Pain Catastrophizing Scale.  
The PCS is a 13 item 5-point Likert scale ranging from 0 (not at all) to 4 (all the 
time). It assesses pain related catastrophizing by asking individuals to recall painful 
experiences and rate the frequency with which they experience catastrophic thoughts 
and feelings. The PCS has well established reliability and validity (Osman et al, 2000; 
Sullivan, 1995). 
Childhood Trauma Questionnaire.  
The CTQ is a 28 item scale indicating levels of retrospective childhood abuse 
and neglect. It contains four scales (physical and emotional abuse, emotional neglect, 
sexual abuse, and physical neglect) containing 5-point  Likert scale items ranging from 
0 (never) to 4 (very often). The CTQ has demonstrated adequate reliability and 
construct validity (Rosen and Martin, 1996). 
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Anxiety Sensitivity Index 
The ASI is a 16 item questionnaire designed to assess the tendency to fear 
anxiety-related bodily sensations based on the belief they may have harmful 
consequences. Each item is rated on a 5 point Likert scale rating from 0 (very little) to 4 
(very much). The ASI has good validity and reliability and has been shown to predict 
fear of pain, escape and avoidance behaviors (Asmundson and Carleton, 2005; 
Asmundson and Taylor, 1996; Norton and Asmundson, 2004). 
Pain Anxiety Symptoms Scale.  
The PASS is a valid 20-item questionnaire that measure anxiety associated with 
pain. Each item is rated on a 6-point Likert scale ranging from 0 (never) to 5 (always). 
The PASS possesses adequate construct and concurrent validities (Staats et al., 2001). 
Beck Depression Inventory. 
          The BDI is one of the most widely used instruments for depression screening in 
psychiatric patients and normal populations (Whisman, Perez & Ramel, 2000). The BDI 
consists of 21 items on a 4-point Likert scale ranging from 0 to 3, with greater 
responses indicating greater degrees of depression. Scores are summed to yield a 
score of 0 to 63. 
Pain measures 
Hargreaves Thermal Withdrawal Test.  
 This test measured phasic (brief escapable pain). Subjects were asked to place their 
non-dominant hand, palm-down, on a glass table suspended above a halogen heat 
source. Subjects were asked withdraw when they can no longer tolerate the 
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temperature. Latency to withdraw was recorded. If subjects failed to withdraw, the light 
was terminated after 20 seconds to prevent tissue injury.  
Modified Submaximal Tourniquet Procedure.  
This test induced exercise ischemic pain in the arm that increases over time 
(Amanzio and Benedetti 1999; Benedetti, 1996; Benedetti et al., 2006; Smith et al., 
1966). The pain felt is that of a strong cramp similar to what one might experience 
during a strenuous workout. Subjects had the venous blood of the non-dominant arm 
exsanguinated by elevating it above the heart for 30 seconds, after which a 
sphygmomanometer (blood pressure cuff) was placed around the upper arm. The 
pressure cuff was inflated to a pressure of 300 mmHg. After this the subject was asked 
to start squeezing a hand exerciser 12 times, each squeeze to last 2 seconds followed 
by a 2 second rest. The discomfort experienced increases over time and the subject 
was asked to rate the intensity of their discomfort on a visual analog scale rating from 0 
(no pain) to 10 (worst possible pain) every minute until conclusion. At the five minute 
mark subjects were asked to squeeze the hand exercise 5 more times and twice more 
at the eight minute mark. The test continued until the subject indicated a desire to 
withdraw or a maximum of 10 minutes have elapsed. Once a desire to withdraw has 
been verbally indicated the pressure cuff was immediately removed. Time to withdraw 
and intensity ratings were recorded. 
Procedure 
Qualified participants in all conditions had both sensory measures explained to 
them in detail and a brief description of the “drugs” to be given. Next, each subject was 
given the Hargreaves Thermal Withdrawal test for a base line measurement. Once the 
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Hargreaves test was conducted each subject was given the MSPQ, PCS and CTQ 
respectively. Upon completion of these three assessment measures each participant 
rolled three di numbering from one to three in a variety of colors. The participant would 
then show the experiment what blue number di they had drawn and was lead to believe 
that this determined which experimental group they had been assigned to. The purpose 
of which was to allow participants to have a sense of control in the selection process. 
The true assignment, however, had been randomly predetermined. 
Following the “randomization” process the experimenter left the room to retrieve 
the “drug” of study which in each case was a size 4 red and white colored gelatin 
capsule containing pure cornstarch. Upon returning, the experimenter explained to the 
participant which drug they were to receive and any potential side effects. 
 Placebo group.  
Subjects assigned to this group were told that they would were told the following 
“For the next part of the study you will be given an anxiolytic, which is a drug that 
reduces anxiety. This drug (P-533), in addition to reducing anxiety, has been 
documented to be a pain reliever as well. This drug is safe and has no negative 
reactions with other medication. It can have the following side effects: sense of 
wellbeing and occasional reports of drowsiness.” After consumption of the pill 
participants were left alone in the testing room without distractions (e.g. cell phones, 
ipods) for 15 minutes to give the “drug” time to take effect. While in truth the purpose of 
the lapse was to allow participants time to ruminate over the coming pain measures for 
15 minutes, which presumably increased test anxiety and increasing group divergence 
allowing for easier statistical discrimination.  
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After 15 minutes had elapsed the experimenter returned to give the remaining 
questionnaires, which consisted of the ASI, PASS and BDI, respectively. Once the 
questionnaires were completed subjects were given a 2nd Hargreaves test followed by 
the tourniquet procedure. After conclusion of the pain measures participants were 
thanked for their time and dismissed. Due to the possibility of participant contamination 
full debriefings are to be conducted at the end of the study. Participants will be 
contacted by email (obtained from informed consent forms) and fully debriefed at that 
time. 
Nocebo group.  
          Subjects assigned to this group were told the following “For the next part of the 
study you will be given a vasoconstrictor, a drug that constricts the blood vessels. This 
drug (N-3556) has been documented to increase pain sensitivity in certain situations, 
specifically with ischemic pain and heat. This drug is safe and has no negative reactions 
with other medication. However, it can have the following side effects: increased heart 
rate, mild headache, increased anxiety and constipation have all been reported. These 
effects have all been documented to be short lived, however.” After consumption of the 
pill participants were left alone in the testing room without distractions (e.g. cell phones, 
ipods) for 15 minutes to give the “drug” time to take effect. While in truth the purpose of 
the lapse was to allow participants time to ruminate over the coming pain measures for 
15 minutes, which presumably increased test anxiety and increasing group divergence 
allowing for easier statistical discrimination.  
           After 15 minutes had elapsed the experimenter returned to give the remaining 
questionnaires, which consisted of the ASI, PASS and BDI, respectively. Once the 
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questionnaires were completed subjects were given a 2nd Hargreaves test followed by 
the tourniquet procedure. After conclusion of the pain measures participants were 
thanked for their time and dismissed. Due to the possibility of participant contamination 
full debriefings are to be conducted at the end of the study. Participants will be 
contacted by email (obtained from informed consent forms) and fully debriefed at that 
time. 
Control group.   
          Subjects assigned to this group were told the following “For the next part of the 
study you will be given an inert talc pill. This pill has no active effects and is being given 
to you because you have been assigned to a control group.” After consumption of the 
pill participants were left alone in the testing room without distractions (e.g. cell phones, 
ipods) for 15 minutes to give the “drug” time to take effect. While in truth the purpose of 
the lapse was to allow participants time to ruminate over the coming pain measures for 
15 minutes, which presumably increased test anxiety and increasing group divergence 
allowing for easier statistical discrimination.  
           After 15 minutes had elapsed the experimenter returned to give the remaining 
questionnaires, which consisted of the ASI, PASS and BDI, respectively. Once the 
questionnaires were completed subjects were given a 2nd Hargreaves test followed by 
the tourniquet procedure. After conclusion of the pain measures participants were 
thanked for their time and dismissed. Due to the possibility of participant contamination 
full debriefings are to be conducted at the end of the study. Participants will be 
contacted by email (obtained from informed consent forms) and fully debriefed at that 
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time. Table 1 indicates the characteristics of all three groups by sex, age and mean 
scores for all six assessment measures. 
Group Sex 
(male/female) 
Age 
(SD) 
MSPQ 
(SD) 
PCS 
(SD) 
CTQ 
(SD) 
ASI 
(SD) 
PASS 
(SD) 
BDI 
(SD) 
Placebo 9/21 
 
22.03 
(2.9) 
 
4.47 
(3.58) 
13.30 
(10.51) 
51.26 
(8.62) 
33.63 
(9.43) 
51.23 
(12.22) 
28.10 
(6.48) 
Nocebo 9/21 
22.13 
(4.2) 
4.50 
(3.25) 
13.87 
(11.30) 
53.13 
(6.60) 
33.37 
(8.10) 
51.30 
(11.99) 
28.13 
(4.61) 
Control 10/20 
20.16 
(8.8) 
4.87 
(3.77) 
13.10 
(10.53) 
54.00 
(7.79) 
32.57 
(7.99) 
48.67 
(14.21) 
28.60 
(8.45) 
Table 1. Characteristics of groups 
Statistical Analysis. 
 MANOVA’s were conducted to establish that all three groups were equitable for 
the predictor variables MSPQ, PCS and CTQ and to establish whether significant group 
differences existed for the hypothesized mediating assessment measures, ASI, PASS 
and BDI, respectively. Repeated measures ANOVA’s and ANCOVA’s were conducted 
to evaluate mean group differences, with and without predictors, for the Hargreaves 
pain measure. Latent Growth Curve Analysis and Cox Regression survival analysis 
were utilized to evaluate the Ischemic arm pain measure, with and without predictors. 
Differences were considered to be statistically significant at p < 0.05. 
Results 
 A one-way MANOVA was conducted to establish whether the groups were 
equitably distributed for the predictor variables MSPQ, PCS and CTQ. These three 
variables were treated as dependent variables for this test. Means and standard 
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deviations are presented in Table 1. Box’s Test of Equality was not significant, p > 0.7, 
indicating the use of Wilk’s Criterion. The combined DV’s were not significant F(6, 170) 
= .386, p=.887, indicating an equitable distribution of predictor variable scores. 
Pain Measure: Hargreaves 
 To test the hypothesis that a difference between group assignment would be 
found a one way ANOVA was conducted. Prior to running the analysis Pre and Posttest 
variables for the Hargreaves were consolidated into one variable, maximum Percent 
Effect (MPE). MPE allows for the clearest distinction of pre and post test scores for the 
individual and was calculated with the following formula: ((test – baseline) / (20 – 
baseline)) X 100. There was no significant difference between groups, F(2,54)=1.080,p 
= .271. Table 2 reports the means and SD for the MPE variable. 
Group N MPE 
Mean 
MPE 
SD 
Placebo 17 -6.7041 132.17 
Nocebo 20 -135.842 393.28 
Control 20 -61.515 189.860 
Table 2. Means and SD for Pre MPE. 
 To evaluate whether the top 10 percent compared to the bottom 50 percent of 
each predictor variable would identify placebo and nocebo responders a new variable 
was created. The large (2008) dataset that established the number of subjects for this 
study was used to establish cut off values for the MSPQ and PCS 10/50 split. Any 
MSPQ score ≥ 12 and ≤4, PCS score ≥ 34 and ≤ 12, and CTQ score ≥ 65 and ≤ 51 
were compiled into a single variable. Any score meeting the top 10 percent cut off was 
coded a 1 and those meeting the bottom 50 percent cut off was coded 0, resulting in 61 
subjects, 14 in the top 10 percent and 47 in the bottom 50 percent. After creating the 
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splitting variable a new ANOVA was conducted with the splitting variable added to 
group membership.. Results, once more, indicate no statistically significant difference 
for group membership (F(2,48) = .727, p = .489) and an interaction of (F(2,48) = .274, p 
= .761. Table 3 reports the means and (SD) for this test. 
Group 10/50 N MPE 
Mean  
MPE 
SD 
Placebo 
50 
10 
14 
3 
-12.697 
21.263 
145.737 
16.696 
Nocebo 
50 
10 
13 
5 
-186.359 
-79.615 
480.588 
103.727 
Control 
50 
10 
14 
5 
-38.662 
-84.669 
173.002 
247.046 
Table 3. Means and SD for MPE. 
 
Pain Measure: Ischemic Arm Test 
 Due to the way this test was measured two types of statistical tests were 
conducted. A Latent growth curve analysis was conducted to handle pain values over 
time and a Cox-Regression Survival analysis was conducted to examine survival 
membership over time. 
 In order to establish a meaningful growth curve model a graph depicting each 
groups mean pain rating over the 10 time points was evaluated (see Figure 1). After 
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Figure 1, mean pain rating by group  
examining the graph a piecemeal model (Figure 2) was selected for two reasons, 1) it 
was believed to best represent the data, as illustrated by the means plot (figure 1) and 
2) it made methodological sense as there was a participant instruction to squeeze the 
hand calipers five more times between time points 5 and 6 resulting in increased pain 
reporting, which is clearly represented in Figure 1. Next, two dummy variables were 
created to allow clearer distinction between groups for the model. Dummy 1 represents 
the placebo group and control while Dummy 2 represents the nocebo group and control. 
3
4
5
6
7
8
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10
Placebo
Control
Nocebo
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Figure 2, Growth Curve Piecemeal model, without predictors. 
 
Results from the estimation of the model depicted in Figure 2 yielded    (68, N=90) = 
367.430, p < .001 suggesting a poor model fit (Byrne, 2010). The RMSEA (Root Mean 
Square Error of Approximation) value for this model is .222 and a CFI (Comparative Fit 
Index) value of .684. Byrne (2010) suggests that a RMSEA value < .05 and a CFI value 
of > .95 is recommended for good model fit. Thus it can be concluded that this model is 
a poor fit of the data. Table 4 provides the regression estimates and p values for this 
model. 
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 Estimate S.E. C.R. p 
Icept    Dummy1 -.164 .650 -.252 .801 
1slope Dummy1  .101 .149  .678 .498 
2slope Dummy1  .025 .272  .093 .926 
Icept    Dummy2  .421 .650  .648 .517 
1slope Dummy2 -.128 .149 -.862 .389 
2slope Dummy2 -.096 .272 -.351 .726 
Table 4 
 
 Next a model adding predictors was evaluated (see Figure 3). The first predictor 
to be evaluated was MSPQ total score. Estimation results from this model yielded    
(93, N=90) = 420.428, p < .001, a RMSEA value of .199 and a CFI value of .719. 
 
Figure 3, Growth Curve Piecemeal model with predictor 
 
Though there was some improvement in RMSEA and CFI values, results indicate this 
model is a poor fit to the data. Examination of regression weights yielded no significant 
p values. 
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 Next, a model replacing MSPQ total scores with PCS total scores was evaluated. 
Estimation results for this model yielded    (93, N=90) = 407.391, p < .001, a RMSEA 
value of .195 and a CFI value of .730. Examination of regression weights yielded no 
significant p values. 
 The next model to be evaluated replaced PCS total scores with CTQ total scores. 
Estimation results for this model yielded    (93, N=90) = 407.391, p < .001, a RMSEA 
value of .195 and a CFI value of .730. Examination of regression weights yielded no 
significant p values, however, the interaction term for placebo and CTQ trended toward 
significance (see table 5). 
 
  
 
 
 
 
 
 
 
Table 5, regression weights; ¹ interaction term for CTQ and placebo. 
 
 Finally, the model depicted in Figure 3 was evaluated with the predictors MSPQ, 
PCS and CTQ combined into one variable using the top 10 percent, bottom 50 percent 
split described earlier. Estimation results for this model yielded    (93, N=90) = 
419.260, p < .001, a RMSEA value of .199 and a CFI value of .680. Examination of the 
regression weights yielded no p value that approached significance. Taken together, all 
models examined exhibited poor model fit and no significant p values. Considering, 
however, the trend toward significance for the interaction term of the CTQ and Placebo, 
 Estimate S.E. C.R. p 
Icept    CTQ -.001 .034 -.029 .977 
1slope CTQ .006 .008 .807 .419 
2slope CTQ .007 .014 .510 .560 
Icept    CTQ int1¹ .094 .055 1.704 .088 
1slope CTQ int1¹ -.022 .011 -.139 .090 
2slope CTQ int1¹ -.043 .023 -1.845 .065 
Icept    CTQ int2 -.034 .048 -.706 .480 
1slope CTQ int2 -.002 .011 -.139 .890 
2slope CTQ int2 .012 .020 .586 .558 
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unplanned secondary analyses were conducted on each of the five subscales 
(emotional abuse, physical abuse, sexual abuse, emotional neglect and physical 
neglect) to determine if any significant effect may have been washed out by only 
examining a total score. 
 Each of the subscales were summed and centered and an interaction term 
created for both Dummy1(placebo) and Dummy 2(nocebo) variables. The subscales 
and their interaction terms were plugged into the model one at a time. Model fit 
remained poor for all subscales, however, a significant effect was found for placebo and 
physical abuse and for placebo and emotional abuse. In addition, a trend toward 
significance was found for emotional neglect and nocebo.  Table 6 reports these 
regression weights and p values. No significant effect or trend was observed for sexual 
abuse or physical neglect and were not included in the following table. 
 
 
 
 
 
  
  
  
 
Table 6, *** p <.001; * p < .05. 
 
 Next, a Cox-Regression survival analysis was conducted to evaluate whether 
ASI, PASS and BDI would predict faster dropout rates beyond that of group 
Physical Abuse Estimate S.E. C.R. p 
Icept    Dummy 1 -6.138 1.818 -3.377 *** 
1slope Dummy 1 .708 .438 1.618 .106 
2slope Dummy 1 1.219 .792 1.540 .124 
Icept    PA x Dummy1 .888 .258 3.435 *** 
1slope PA x Dummy1 -.086 .062 -1.378 .168 
2slope PA x Dummy1 -.176 .113 -1.567 .117 
Emotional Abuse     
Icept    EA x Dummy1 .519 .182 2.857 .004* 
1slope EA x Dummy1 -.092 .043 -2.142 .032* 
2slope EA x Dummy1 -.178 .079 -2.255 .024* 
Emotional Neglect     
Icept    EN x Dummy2 -.326 .178 -1.834 .067 
1slope EN x Dummy2 .005 .041 .117 .907 
2slope EN x Dummy2 .078 .074 1.052 .293 
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membership and the top 10, bottom 50 percent split. The dummy code variables for 
group membership used in the growth curve analysis were used in this analysis as 
recommended by Tabachnick and Fidell (2007) for regression analysis. Group 
membership (dummy1 and dummy2) and the 10/50 split (allsplit) were entered as 
covariates in the first block, ASI, PASS and BDI scores were entered into the second 
block. At no time did the model become significant (  (6) = 5.753, p = .451), however, 
ASI scores contributed significant variance to the prediction of dropout rates (see Table 
7 for results).  
 
 B SE Wald DF Sig Exp(b) 
Dummy1 .506 .487 1.077 1 .299 1.658 
Dummy2 .402 .501 .644 1 .422 1.494 
Allsplit .175 .512 .117 1 .732 1.191 
ASI .059 .028 4.383 1 .036 1.061 
PASS -.012 .018 .438 1 .508 .988 
BDI -.032 .036 .825 1 .364 .968 
Table 7 
 
 Finally, no mediation tests were conducted for anxiety and depression variables 
due to a lack of significance on any model examined thus far. A SOBEL mediation test 
requires a significant direct path correlation before the indirect path can be examined. 
 
Discussion 
 In this study, an attempt was made to identify placebo/nocebo responders based 
on coping styles that were hypothesized to affect expectation. These coping styles were 
described as somatization, catastrophizing and child-hood trauma all of which have 
been documented to influence pain perception and outcomes (Sullivan et al., 2001; 
Fillingim and Edwards, 2005; Heckman and Westefeld, 2006; Geers et al., 2006). 
Additionally, an attempt was made to evaluate the extent anxiety and depression might 
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mediate placebo/nocebo responsiveness. The results of planned analyses indicated 
that the anxiety sensitivity index (ASI) contributed significantly to drop out rates in the 
survival analysis. This is not surprising as anxiety has been repeatedly demonstrated to 
influence placebo and nocebo responses, with reduced anxiety associated with placebo 
effects and increased anxiety associated with nocebo effects (Benedetti et al., 2006; 
2007; Colloca and Benedetti, 2007; Gatchel et al., 2007; Geers et al., 2005; Keogh et 
al., 2006; Loeser and Melzack, 1999; Ploghous et al., 2001). This contribution, however, 
failed to significantly improve the overall survival model and was the only component of 
any planned analysis to reach significance. There was, however, an encouraging trend 
found in childhood trauma scores and placebo responsiveness that warranted further 
unplanned analysis. 
 The placebo/nocebo effect is a well-established phenomenon that has been 
demonstrated using a variety of pain paradigms by numerous studies (Amanzio and 
Benedetti, 1999; Benedetti, 2007; Benedetti & Amanzio, 1997; Benedetti et al., 2007; 
Colloca and Benedetti, 2007; Colloca et al., 2008; Enck et al., 2008; Klosterhalfen and 
Enck, 2008; Kong et al., 2008). Considering the well-established nature of the 
placebo/nocebo effect it is surprising that little to no effect was observed for the 
proposed hypotheses. One could reasonably conclude a methodological flaw is washing 
out these primary effects. 
  The discussion, then, will focus on two areas. First, the author will discuss the 
unplanned childhood trauma results. Second, the potential pitfalls and limitations that 
may have negatively affected the outcome and suggestions for models that would 
overcome these deficits are covered. 
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Unplanned Analyses: Childhood Trauma 
 Because childhood trauma questionnaire total scores trended toward a 
significant interaction between childhood trauma and placebo responsiveness further 
analyses were conducted on each of the five subscales contained in the CTQ. It was 
believed that such analyses might reveal effects that were washed out by the 
combination of all scales into a single score.  
 The initial hypothesis about childhood trauma was that it would be an experience 
resulting in a negative coping style, thus resulting in more susceptibility to negative 
information. In this case the suggestion of pain worsening (nocebo). As mentioned 
previously, research has demonstrated that early childhood trauma and adversity is 
predictive for the onset of back pain in adulthood (Kopec and Sayre, 2005) and has 
been related to poor outcome following back surgery (Shofferman et al., 1993). 
Additionally, It is believed that childhood trauma involving abuse or neglect may 
influence the way one perceives future painful events (Fillingim and Edwards, 2005; 
Heckman and Westefeld, 2006) based on past experiences.  
 The results indicated that childhood trauma does indeed influence future painful 
events. Apparently, it is not unidirectional, as the author hypothesized. Physical and 
emotional abuse significantly predicted placebo responsiveness but not nocebo 
responsiveness. This finding is clearly opposite to the model posited. Sexual abuse did 
not influence responsiveness in either direction, nor did physical neglect. Emotional 
neglect, however, trended toward nocebo responsiveness but not placebo. 
 It is not immediately clear why such divergence in responsiveness was found. 
The literature provided the author with little information directly related to the topic. 
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Fillingim and Edwards (2005) noted that subjects who self-reported sexual and physical 
abuse had a decreased sensitivity to repetitive thermal stimulation but not to ischemia 
pain. They also indicated that those with self-reports of abuse perceived themselves to 
be in poorer health and reported greater negative affect than non-abuse groups. The 
authors had no clear explanation for why there was a difference in response to brief 
pain versus more intense pain. They did, however, suggest that somatic focus could be 
a contributing factor. In fact, Geers et al. (2006) investigated the role of somatic focus 
and placebo responding and found that individuals who were instructed to somatically 
attend to a drug’s effects were more likely to be a placebo responder than those that 
were not attending. This is in keeping with this study’s inclusion of somatization as a 
factor in placebo/nocebo responsiveness. 
 It is problematic, however, in that somatization as a predictor did not produce an 
effect in this study. This does not rule out the possibility that somatic focus could be a 
mechanism interacting with physical and emotional abuse in such a way that 
predisposes an individual to look for positive information that a painful condition is about 
to be relieved. It is also possible somatic focus of negative information is an outcome of 
emotional neglect. One must keep in mind that this study focused on non-clinical 
populations and such a mechanism may only be temporarily effective, if it exists at all. 
In a clinical pain population it may be that physical and sexual abuse then increases the 
likelihood of poorer outcomes as the literature indicates. 
 The one clear point is that much more research needs to be conducted to 
elucidate the mechanisms involved. Additionally, caution must be used in any 
interpretation of this data as the population was non-clinical. This naturally resulted in 
35 
 
small samples for the abuse, neglect subscales of the CTQ and could very well be 
random occurrence. Though little difference was found between groups in this study as 
a whole, it is encouraging that significant effects were observed for childhood trauma 
and placebo/nocebo responsiveness. Even if the effects were the result of statistical 
randomness further investigation is warranted, which leads to the remaining discussion 
of this study’s strengths, weaknesses and suggested modifications. 
 
Study Strengths 
 Although there were no significant statistical main effect findings one can still 
optimistically conclude that a number of sound design elements existed in this study. 
The choice of predictor variables has been demonstrated to influence pain perceptions 
and outcomes (Sullivan et al., 2001; Fillingim and Edwards, 2005; Heckman and 
Westefeld, 2006; Geers et al., 2006) and has been scrutinized for validity and reliability 
(Main, 1983; Osman et al, 2000; Sullivan, 1995; Rosen and Martin, 1996). 
 Though no mediation tests could be conducted on the anxiety measures their 
inclusion for consideration is in keeping with the literature. Additional support for 
inclusion of anxiety measures in this study comes indirectly from the Cox Regression 
survival analysis. The ASI contributed significant variance to the prediction of dropout 
rates, p = .036, however, failed to bring the total model to significance. Thus, caution is 
warranted in interpreting this result. That said, it could reasonably be concluded that a 
similar study would benefit from the inclusion of anxiety measures. 
 The Hargreaves Thermal Withdrawal test is not generally conducted in 
placebo/nocebo studies. However, it is the author’s opinion that inclusion of this pain 
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measure can be considered a study strength for two reasons. First, the measure is brief 
which allowed for a pre and posttest in the same experimental session. Second, the 
following table, illustrates the differences between groups that are traditionally expected. 
A clear indication the measure is sound. 
Group N MPE 
Mean 
MPE 
SD 
Placebo 17 -6.7041 132.17 
Nocebo 20 -135.842 393.28 
Control 20 -61.515 189.860 
Table 8. Means and SD for Pre MPE. 
 Inclusion of the ischemic pain measure can generally be considered a study 
strength. It is a well-established measure first developed by Smith et al., (1966) and 
validated by Smith et al., (1968) for use in analgesia pain studies. Since its development 
it has been commonly and reliably used to detect placebo and nocebo effects, 
especially by the Benedetti research group (Amanzio and Benedetti 1999; Benedetti, 
1996; 1997; Benedetti et al., 1997 Benedetti et al., 2003; Benedetti et al., 2006). Further 
support of this measure can be gleaned from examination of Figure 1, in which mean 
scores of the VAS 10 time points are trending toward expected results. 
 Lastly, as noted in the introduction fewer than 4% of placebo studies have 
included a no-placebo control group in which to evaluate claimed effects (Ernst and 
Resch, 1995; Fisher, 2000; Geer et al., 2005). Not only did this study include a control 
group the groups were conditional. Price, Finniss and Benedetti (2008) reported “Verbal 
suggestions that induce certain expectations of analgesia induce larger placebo 
responses than those inducing uncertain expectations.” In other words, groups that are 
told what to expect (conditional) experience larger placebo effects than groups that are 
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not told what to expect (unconditional). Despite the many perceived strengths of this 
study, clearly there were significant weaknesses that managed to diminish the outcome. 
Study Weaknesses 
 Though there is no real way in which to quantify the weaknesses of this study, 
reflection on the procedures used and revisiting the literature has provided the author 
with several suspected deficiencies. The primary suspected deficiency was the strength 
of the suggestions used. There are gradations of suggestion strength in regards to the 
placebo/nocebo response. Olshansky (2007) states: 
Placebo strength varies by the type of intervention. A dose response 
exists. Blue (vs. pink) placebo pills are sedating. Yellow (vs. green) 
placebo pills are stimulating. Red (vs. beige) placebos encourage a 
cardiac response. Branded ismore effective than generic. Four-times-a-
day is more potent than twice-a-day. Larger capsules are stronger than 
smaller ones. Interventions, injections, andsurgery give larger effects than 
pills. 
 
The above statement was echoed by Benedetti and Amanzio (1997) and Williams 
(2004).  
 Participants in this study told that the “drugs” being investigated were of a short 
duration and considered safe to take with other medications with few side effects. The 
purpose of the generally weak suggestion was to alleviate participant concerns, thus 
increasing participant numbers. However, reviewing the literature found Benedetti using 
phrases like “powerful” and “strong” when explaining pill or injection effects (Benedetti et 
al., 2006). If, as posited in the introduction, placebo and nocebo effects are contingent 
on expectancies then a weak expectancy could very well have driven the weak to non-
existent results found in this study. Without a primary difference observed between 
groups then all other analyses would necessarily fail. 
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 Though listed as strengths both pain measures also had their weaknesses that is 
believed to have contributed to the difficulties observed in this study. The primary pain 
measure in this study was ischemia pain induced by the tourniquet technique. This 
study used a modified version of the technique described by Benedetti (1996). Amanzio 
and Benedetti (1999) noted that tolerance and pain variability was observed if the 
sphygmomanometer cuff was not maintained at 300mmHg and an Esmarch bandage 
(pressure bandage) maintained on the forearm for the duration of the test (10 minutes).  
 In this study the sphygmomanometer cuff was maintained at 300mmHg, 
however, due to concerns about potential participant injury an Esmarch bandage was 
not applied to the forearm. In revisiting the literature the author determined a 
misunderstanding about the Esmarch bandage had taken place. Originally the Esmarch 
bandage was a rubber tube approximate the width of a finger and could be tightened 
into a tourniquet. More recently the Esmarch bandage is a wider latex bandage, also 
known as a Martin bandage, and is used primarily as a pressure bandage, not as a 
tourniquet (Fletcher and Healy, 1983). The initial literature review led the author to 
believe that inappropriate application of an Esmarch bandage could lead to participant 
injury and was thus discarded from consideration. 
 Additionally, the ischemia test was only applied once. Initial consideration was 
given to a repeated measures administration but was discarded for concern it would 
have a significant impact on continued subject participation. In other words, there was 
concern that subjects would drop from the study once they had experienced the 
discomfort generated by this test. Returning to the literature has convinced the author 
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that repeating this test would be the most effective technique in establishing 
placebo/nocebo responses. 
 Finally, the ischemic arm test was measured and analyzed using a VAS pain 
rating each minute over a ten minute time frame. Though this was the main measure 
used by Benedetti (1996; 2006), alternative applications of this technique were modified 
to be measured as length of time from last hand caliper squeeze to unbearable pain. 
This measure generally induces ischemic arm pain quickly and becomes unbearable in 
about 13 to 14 minutes (Amanzio and Benedetti 1999; Benedetti, 1996; 1997; Benedetti 
et al., 1997 Benedetti et al., 2003; Benedetti et al., 2006). This study did not observe a 
quick increase in pain. In fact, several subjects noted a lessening in discomfort after the 
initial application of the blood pressure cuff. Taken together, this measure, as utilized in 
this study, likely contributed significantly to the lack of effect observed between groups. 
 Turning next to the Hargreaves Thermal Withdrawal test, though also listed as a 
strength in the study it too had observable weaknesses. During administration of the 
test it was suspected that a number of subjects misunderstood the verbal instructions of 
the test. Several others complained the glass top was cold to the touch and perhaps 
interfered with detection of the heat stimulus. Finally, several subjects in a row timed out 
on the pre and post test leading the experimenter to believe that the apparatus settings 
had been altered in some fashion. In all, 25 subjects had to be eliminated for ceiling 
effects on analyses that involved this test potentially contributing to non-significant 
effects. 
 Finally, it should be considered that contamination of the subject pool may have 
influenced expectations. A number of participants mentioned to the experimenter that 
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they had discussed the study with other participants prior to their appointment and knew 
what to expect in terms of procedure and drug strength. It is not clear to what degree, if 
any, this foreknowledge may have influenced outcome. 
Conclusion 
 The author believes that this study was fundamentally sound but 
methodologically weak in the areas noted above. To address these issues two potential 
study designs could be considered. First, a study primarily identical to this one with the 
following changes in design. 1) Moving from a weak suggestion to a strong suggestion 
and including an injection instead of a pill would largely alleviate this weakness. 2) 
Modifying the ischemic arm test to include an Esmarch bandage to increase 
exsanguination speed and reduce variations in pain responsiveness. 3) Moving from a 
VAS measurement of pain to a time to unbearable pain measurement would likely 
alleviate the considerable subjective ambiguity observed in the VAS measurement. An 
instruction of “tell me when the discomfort is unbearable” is much less confusing than a 
scale containing “worse pain imaginable”. It was observed that a number of subjects in 
the current study gave significant consideration to the “meaning” of “worse pain 
imaginable”. 4) Moving to a repeated measure of the Ischemia test would enhance 
detection of effects and be more in keeping with existing literature. 5) Finally, 
instructions clarifying the Hargreaves test, a daily settings check and efforts to alleviate 
the “cold” sensation of the glass table top would conclude modifications to a subsequent 
study based on the initial premises. 
 Alternatively, an animal neglect model could be proposed. Moving to an animal 
model would allow more objective testing on several hypotheses considered in the 
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present study. Though somatization and catastrophizing could not be directly assessed 
in an animal model childhood trauma could be manipulated and its effects on pain could 
be directly observed. Such a model would involve separating rat pups for extended 
periods of time from their mothers to approximate emotional neglect and surgically 
injuring others to approximate physical abuse. Though such manipulations might seem 
cruel, an Institutional Animal Care and Use Committee (IACUC) approval has been 
given at UNO for a similarly designed study.  
 Manipulating rearing situations and comparing them to non-manipulated animals 
has the obvious advantage of control of conditions. Fewer subjects can be used 
because all subjects have known histories with precisely controlled interventions. This is 
unlike human studies in which larger numbers of participants are needed to obtain 
adequate numbers of individuals with desired predictor variable scores. Even then, 
large variations in personal histories and experiences will exist in a human subjects 
study creating the possibilities that some experience or another may have been 
overlooked in design consideration. 
 Deception is a primary component of placebo and nocebo studies. Considering 
this, one might wonder how you lie to a rat. The answer would presumably be that you 
violate conditioned expectations. Hernstien (1962) and Ader and Cohen (1975) 
demonstrated that placebo responses could be conditioned in animals. Thus, by 
extension, a model that manipulates conditioning would mimic the deception process 
used in human models. For example, over the course of several trials a drug like 
morphine or valium could be administered to an animal and given a saline solution 
injection (placebo) on a final trial to violate expectancies. Nocebo might be 
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accomplished by giving several trials of saline solution followed by Complete Freund’s 
Adjuvant (CFA), a water-in-oil emulsion that contains a pain inducing agent, mimicking a 
negative violation of expectancy. Though an extensive literature review is necessary to 
completely work out the mechanics of an animal model it should be clear that such a 
model is possible and would have distinct methodological advantages.  
 In summary, it is the author’s assertion that though the present study had no 
significant primary findings it has a number of sound premises which was illustrated by 
the unplanned CTQ analysis. A more comprehensive study built from the information 
here that addresses the weaknesses mentioned by utilizing a subsequent human model 
study or more precisely controlled animal model is warranted. 
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